DOCUMENTARY RESEARCH · UNITED STATES
Take a closer look at the questions that matter when reading a provider’s offer.
READING GUIDE
Approval status, clinical trial results, pharmacy claims and individualized medical need answer different questions. Here is how to read them without assuming either equivalence or inequivalence.
READING GUIDE
NIDDK frames ongoing weight-management care around response, tolerability and changing circumstances. Public documents from six GLP-1 services show why messaging, refills, laboratory testing and billing should be examined separately.
READING GUIDE
Before accepting a weight-loss percentage or a promise of better tolerability, check who was studied, what they received, what it was compared with—and whether the evidence actually concerns the service being sold.
READING GUIDE
Semaglutide and tirzepatide appear across brand-name products, compounded injections, vitamin blends and microdosing programs. The ingredient name is only the beginning of an evidence check.
READING GUIDE
Drug studies, provider promises and patient-service records answer different questions. Here is how to read GLP-1 marketing without treating one kind of evidence as another.
READING GUIDE
GLP-1 study averages describe groups under specific research conditions. They do not forecast your outcome—or establish how well a telehealth provider’s products work.
READING GUIDE
Provider websites can document advertised prices, service responsibilities and refund rules. They cannot, by themselves, verify licensing or establish the clinical performance of a telehealth program.
READING GUIDE
FDA reports can identify concerns worth investigating. Without a denominator or established causation, they cannot supply a side-effect rate, rank telehealth companies or predict your experience.
READING GUIDE
The 68-week trial found mean weight changes of −14.9% with studied injectable semaglutide and −2.4% with placebo. Understanding that finding requires the population, lifestyle support, tolerability, funding and product boundaries—not just the headline.
READING GUIDE
FDA’s warning about warm injectable deliveries is specific. “Fast shipping,” pharmacy partnerships and clinical trial results answer different questions—and none independently verifies a package’s temperature history.
READING GUIDE
A practical guide to checking citations, separating provider claims from clinical evidence, and understanding what a consultation date does—and does not—tell you.
READING GUIDE
The tirzepatide trial offers important evidence about studied treatment groups—not a scorecard for telehealth companies, compounded formulations or individual results.